Hybrid Nano-carriers for Potential Drug Delivery
Abstract
Nanocarriers have provided the versatile platform for the delivery of various therapeutic and diagnostic agents. Liposome, niosomes, polymeric and solid lipid nanoparticles are the most promising nanocarriers that have been entered in the clinical trials and become commercially available. However, each system has been associated with some problems that can be minimized by using the combinatorial approach of hybrid nanocarriers. These hybrid systems combine the benefits of different structural components to synergize the outcome of the therapy. In this chapter, the different types of hybrid nanocarriers have been described with particular emphasis on the brief rationale for the development of these hybrid nanocarriers along with different fabrication approaches with greater emphasize on the lipid polymer hybrid nanoparticles. A brief description factors governing the optimized response characteristics and their potential application of these hybrid nanoparticles are also presented.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.